$2.68T
Total marketcap
$45.9B
Total volume
BTC 49.83%     ETH 17.12%
Dominance

Fate Therapeutics FATE Stock

3.43 USD {{ price }} -3.107342% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
390.44M USD
LOW - HIGH [24H]
3.36 - 3.57 USD
VOLUME [24H]
2.75M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.92 USD

Fate Therapeutics Price Chart

Fate Therapeutics FATE Financial and Trading Overview

Fate Therapeutics stock price 3.43 USD
Previous Close 5.43 USD
Open 5.41 USD
Bid 0 USD x 800
Ask 0 USD x 2200
Day's Range 5.36 - 5.96 USD
52 Week Range 4.02 - 37.13 USD
Volume 2.55M USD
Avg. Volume 2.56M USD
Market Cap 571.61M USD
Beta (5Y Monthly) 1.48838
PE Ratio (TTM) N/A
EPS (TTM) -1.92 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 8.16 USD

FATE Valuation Measures

Enterprise Value 232.95M USD
Trailing P/E N/A
Forward P/E -2.905
PEG Ratio (5 yr expected) 0.08
Price/Sales (ttm) 4.1764493
Price/Book (mrq) 1.1947358
Enterprise Value/Revenue 1.702
Enterprise Value/EBITDA -0.942

Trading Information

Fate Therapeutics Stock Price History

Beta (5Y Monthly) 1.48838
52-Week Change -72.38%
S&P500 52-Week Change 20.43%
52 Week High 37.13 USD
52 Week Low 4.02 USD
50-Day Moving Average 5.58 USD
200-Day Moving Average 12.12 USD

FATE Share Statistics

Avg. Volume (3 month) 2.56M USD
Avg. Daily Volume (10-Days) 2.34M USD
Shares Outstanding 98.38M
Float 83.7M
Short Ratio 12.67
% Held by Insiders 1.50%
% Held by Institutions 106.35%
Shares Short 29.12M
Short % of Float 37.96%
Short % of Shares Outstanding 29.58%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -171.63%
Operating Margin (ttm) -191.80%
Gross Margin -128.55%
EBITDA Margin -180.70%

Management Effectiveness

Return on Assets (ttm) -22.042%
Return on Equity (ttm) -42.29%

Income Statement

Revenue (ttm) 136.87M USD
Revenue Per Share (ttm) 1.41 USD
Quarterly Revenue Growth (yoy) 220.29%
Gross Profit (ttm) -224154000 USD
EBITDA -247323008 USD
Net Income Avi to Common (ttm) -234912000 USD
Diluted EPS (ttm) -2.43
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 408.9M USD
Total Cash Per Share (mrq) 4.16 USD
Total Debt (mrq) 107.62M USD
Total Debt/Equity (mrq) 22.54 USD
Current Ratio (mrq) 9.001
Book Value Per Share (mrq) 4.863

Cash Flow Statement

Operating Cash Flow (ttm) -212455008 USD
Levered Free Cash Flow (ttm) -131318376 USD

Profile of Fate Therapeutics

Country United States
State CA
City San Diego
Address 12278 Scripps Summit Drive
ZIP 92131
Phone 858 875 1800
Website https://www.fatetherapeutics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 551

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Q&A For Fate Therapeutics Stock

What is a current FATE stock price?

Fate Therapeutics FATE stock price today per share is 3.43 USD.

How to purchase Fate Therapeutics stock?

You can buy FATE shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Fate Therapeutics?

The stock symbol or ticker of Fate Therapeutics is FATE.

Which industry does the Fate Therapeutics company belong to?

The Fate Therapeutics industry is Biotechnology.

How many shares does Fate Therapeutics have in circulation?

The max supply of Fate Therapeutics shares is 113.83M.

What is Fate Therapeutics Price to Earnings Ratio (PE Ratio)?

Fate Therapeutics PE Ratio is now.

What was Fate Therapeutics earnings per share over the trailing 12 months (TTM)?

Fate Therapeutics EPS is -1.92 USD over the trailing 12 months.

Which sector does the Fate Therapeutics company belong to?

The Fate Therapeutics sector is Healthcare.

Fate Therapeutics FATE included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16920.58 USD
-0.58
6.33B USD 16873.97 USD 16989.6 USD 6.33B USD
NASDAQ Composite Total Return I XCMP 20585.06 USD
-0.58
20528.35 USD 20669.02 USD
NASDAQ Global Market Composite NQGM 2227.56 USD
-0.91
2210.18 USD 2234.21 USD
NASDAQ Biotechnology NBI 4311.81 USD
-1.19
4286.36 USD 4323.39 USD
NASDAQ HealthCare IXHC 967.78 USD
-1.12
964.91 USD 969.79 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2092.23 USD
-1.44
2090.93 USD 2099.3 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD